Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial-Reference-Cited by-同舟云学术

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Published:2013-04 Issue:9873 Volume:381 Page:1203-1210
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Rummel Mathias J,Niederle Norbert,Maschmeyer Georg,Banat G Andre,von Grünhagen Ulrich,Losem Christoph,Kofahl-Krause Dorothea,Heil Gerhard,Welslau Manfred,Balser Christina,Kaiser Ulrich,Weidmann Eckhart,Dürk Heinz,Ballo Harald,Stauch Martina,Roller Fritz,Barth Juergen,Hoelzer Dieter,Hinke Axel,Brugger Wolfram

Publisher

Elsevier BV

Subject

General Medicine

Reference24 articles.

1. Cancer statistics, 2009;Jemal;CA Cancer J Clin,2009

2. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997;Harris;Ann Oncol,1999

3. Rituximab: mechanism of action;Weiner;Semin Hematol,2010

4. Follicular lymphoma, survival, and rituximab: is it time to declare victory?;Horning;J Clin Oncol,2008

5. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

Cited by 1234 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL;Blood;2024-09-05

2. Successful treatment with PR-mini-CHP for elderly relapsed and refractory mantle cell lymphoma;2024-09-03

3. Approach to Untreated Follicular Lymphoma, Where Are We Now and Future Directions;Clinical Lymphoma Myeloma and Leukemia;2024-09

4. Current Management of Waldenstrom Macroglobulinemia;Clinical Lymphoma Myeloma and Leukemia;2024-09

5. Optimal number of cycles of bendamustine as initial chemoimmunotherapy for older patients with follicular lymphoma;Blood Neoplasia;2024-09